Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 18, 2026

2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of

View original at finance.yahoo.com
2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of Urban air mobility has long lived somewhere between science fiction and city planning decks…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • For Archer fiscal 2026, losses expected to reduce 7.8% annually to -$0.95 per share

    80% confidence

  • For Joby, full fiscal year losses seen growing 7.6% annually to -$0.85 per share

    80% confidence

  • For Joby, current quarter loss per share expected to widen 5.3% YOY to -$0.20

    80% confidence

  • Wall Street analysts recommend caution with consensus Hold rating for Joby Aviation

    80% confidence

  • For Archer current year, losses projected to decline 27.5% YOY to -$1.03 per share

    80% confidence

  • Urban air mobility has long lived somewhere between science fiction and city planning decks

    80% confidence

  • For Archer current quarter, losses expected to decrease 52.8% YOY to -$0.25 per share

    80% confidence

  • Management expects to generate cash, cash equivalents, and short-term investments at the upper end of $500 million to $540 million range for 2025

    80% confidence

  • For Joby fiscal 2026, loss projected to narrow 11.8% to -$0.75 per share

    80% confidence

  • Archer Aviation has consensus Moderate Buy rating overall

    80% confidence

  • Joby plans to produce four aircraft a month by 2027 at Ohio facility

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of — Source | Via News | Finance Via News